ATE513556T1 - Hgfr-bindungsort mit hoher affinität und verfahren zur identifizierung von antagonisten desselben - Google Patents

Hgfr-bindungsort mit hoher affinität und verfahren zur identifizierung von antagonisten desselben

Info

Publication number
ATE513556T1
ATE513556T1 AT09159644T AT09159644T ATE513556T1 AT E513556 T1 ATE513556 T1 AT E513556T1 AT 09159644 T AT09159644 T AT 09159644T AT 09159644 T AT09159644 T AT 09159644T AT E513556 T1 ATE513556 T1 AT E513556T1
Authority
AT
Austria
Prior art keywords
binding site
high affinity
identifying antagonists
hgfr binding
hgfr
Prior art date
Application number
AT09159644T
Other languages
English (en)
Inventor
Paolo Maria Comoglio
Paolo Carminati
Paolo Michieli
Cristina Basilico
Original Assignee
Metheresis Translational Res Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Res Sa filed Critical Metheresis Translational Res Sa
Application granted granted Critical
Publication of ATE513556T1 publication Critical patent/ATE513556T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT09159644T 2008-05-14 2009-05-07 Hgfr-bindungsort mit hoher affinität und verfahren zur identifizierung von antagonisten desselben ATE513556T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08103958 2008-05-14

Publications (1)

Publication Number Publication Date
ATE513556T1 true ATE513556T1 (de) 2011-07-15

Family

ID=40984839

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09159644T ATE513556T1 (de) 2008-05-14 2009-05-07 Hgfr-bindungsort mit hoher affinität und verfahren zur identifizierung von antagonisten desselben

Country Status (18)

Country Link
US (4) US8404453B2 (de)
EP (1) EP2119448B1 (de)
JP (1) JP5623027B2 (de)
KR (1) KR101509263B1 (de)
AT (1) ATE513556T1 (de)
BR (1) BRPI0901502A2 (de)
CA (1) CA2665958C (de)
CY (1) CY1111853T1 (de)
DK (1) DK2119448T3 (de)
EA (1) EA017863B1 (de)
ES (1) ES2368603T3 (de)
HR (1) HRP20110643T1 (de)
IL (1) IL198545A0 (de)
MX (1) MX2009005049A (de)
PL (1) PL2119448T3 (de)
PT (1) PT2119448E (de)
SG (1) SG157312A1 (de)
SI (1) SI2119448T1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
EP3165538A1 (de) 2010-11-03 2017-05-10 Argen-X Nv Anti-c-met-antikörper
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2773660A2 (de) 2011-11-03 2014-09-10 Argen-X B.V. Chimäre mensch-kamel-antigene und ihre verwendung
WO2013079973A1 (en) * 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
US11035860B2 (en) 2014-11-20 2021-06-15 Stichting Katholieke Universiteit Auto-active and intracellular mutant of MET
EP3519440A4 (de) 2016-09-29 2020-03-25 Mitsubishi Tanabe Pharma Corporation Monoklonale cmet-bindemittel, wirkstoffkonjugate davon und verwendungen davon
CN113567685B (zh) * 2021-09-26 2022-05-17 瑞博奥(广州)生物科技股份有限公司 基于核酸适配体探针的hgfr识别方法及检测hgfr的试剂盒
CN116121255A (zh) * 2022-12-20 2023-05-16 中国科学院基础医学与肿瘤研究所(筹) 一种结合hgfr蛋白的核酸适配体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3293823B2 (ja) * 1991-05-10 2002-06-17 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー 肝細胞成長因子（ｈｇｆ）レセプターの部分切除形態
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
AU2760602A (en) 2001-03-23 2002-09-26 Agouron Pharmaceuticals, Inc. Catalytic domains of the human hepatocyte growth factor receptor tyrosine kinase, and materials and methods for identification of inhibitors thereof
WO2007036945A2 (en) 2005-09-30 2007-04-05 Compugen Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
CN1922208A (zh) 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
US20060069019A1 (en) 2004-05-06 2006-03-30 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor beta chain with Met receptor and methods of use
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
EP1911459B1 (de) * 2005-07-28 2015-12-02 AnGes MG, Inc. Mittel zur förderung der lymphangiogenese
ES2368864T3 (es) * 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof

Also Published As

Publication number Publication date
EP2119448B1 (de) 2011-06-22
US8404453B2 (en) 2013-03-26
KR101509263B1 (ko) 2015-04-06
MX2009005049A (es) 2009-12-18
PL2119448T3 (pl) 2011-11-30
BRPI0901502A2 (pt) 2010-01-26
JP5623027B2 (ja) 2014-11-12
EP2119448A1 (de) 2009-11-18
SG157312A1 (en) 2009-12-29
SI2119448T1 (sl) 2012-02-29
US20130183690A1 (en) 2013-07-18
DK2119448T3 (da) 2011-09-26
US20120108789A1 (en) 2012-05-03
PT2119448E (pt) 2011-09-27
US9121854B2 (en) 2015-09-01
US20120115219A1 (en) 2012-05-10
EA200900537A1 (ru) 2009-12-30
EA017863B1 (ru) 2013-03-29
HRP20110643T1 (hr) 2011-10-31
CY1111853T1 (el) 2015-11-04
US20090298079A1 (en) 2009-12-03
US9310377B2 (en) 2016-04-12
KR20090118846A (ko) 2009-11-18
CA2665958C (en) 2014-01-07
AU2009201893A1 (en) 2009-12-03
CA2665958A1 (en) 2009-11-14
IL198545A0 (en) 2011-07-31
JP2009291191A (ja) 2009-12-17
ES2368603T3 (es) 2011-11-18

Similar Documents

Publication Publication Date Title
DK2119448T3 (da) HGFR-bindingssite med høj affinitet og fremgangsmåder til identifikation af antagonister deraf
ATE477249T1 (de) Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
ATE533502T1 (de) Verfahren zur modulation der il-23-aktivität; relevante reagenzien
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
GB2433937A (en) Porous inorganic/organic hybrid materials with ordered domains for chromatographic separations and processes for their preparation
DE602005002853D1 (de) Vorrichtungen zum Reparieren von lebendem Gewebe
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
EP2134854A4 (de) Behandlungsverfahren unter verwendung von egfr-antikörpern und src-inhibitoren und damit verbundene formulierungen
ATE481099T1 (de) Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten
DE602005005230D1 (de) Vorrichtung und Verfahren zum Zusammenführen von Bildbereichen mit ähnlichen Eigenschaften
DE602005003551D1 (de) Blocksystem und -Verfahren zum sicheren Fahrbetrieb von Bahnstrecken mit niedrigerer Verkehrsdichte
DE602005003075D1 (de) Anordnung, Verfahren und Programm zur Bestimmung der Position von Gesichtsteilen
EP2136511A4 (de) Verfahren, gerät und system zur kombination von resourcenzulassungskontrolle
DE602007007352D1 (de) Textilbehandlungsverfahren und zusammensetzung zur verleihung differentieller hydrophobie
EP2340039A4 (de) Verwendung von il-20-antagonisten zur behandlung von rheumatioder arthritis und osteoporose
DE602006008098D1 (de) Verfahren und System zur Verwaltung von Datenverkehr
DE602006015182D1 (de) Zusammensetzung und verfahren zur kontrolle von insekten
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo
EP1888106A4 (de) Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen
EP1809742A4 (de) Verfahren zur behandlung von mit der akkumulation überschüssiger extrazellulärer matrix assoziierten leiden
ATE512133T1 (de) 1h-pyrrol-2-carbonsäureamide und imidazol-5- carbonsäureamide und deren verwendung als fak-, kdr- und tie2-kinase-modulatoren zur behandlung von krebs
BRPI0809304A2 (pt) Método para tratar material de revestimento de cuba de gasto contendo carbono e/ou material inorgânico
DE602005022686D1 (de) Einpressmörtelmischung zur verwendung bei einer spannbetonkonstruktion
ATE495752T1 (de) Verfahren und zusammensetzungen zur notfallbedingten verhütung mithilfe von endothelin-rezeptor-antagonisten
EP1814553A4 (de) Gtpase-hemmer und deren verwendung zur regulierung von thrombozytenhyperaktivität

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2119448

Country of ref document: EP